Ensysce Biosciences
LA JOLLA, California, United States · Banking, Biotechnology, Finance
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the use of potent prescription drugs, reducing abuse and preventing overdoses.
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- LA JOLLA, California, United States
- Employees
- 12
- Industries
- Banking, Biotechnology, Finance
- Status
- Public (ENSC)
- Website
- ensysce.com
- Company page
Recent activity at Ensysce Biosciences
- : SEC 8-K (8.01): On August 25, 2026, Ensysce Biosciences Inc. received notification from Nasdaq confirming that the company complies with the $2.5 million stockholders’ equity requirement under Rule 5550(b)(1). This followed a previous notice on May 21, 2026, regarding potential delisting due to non-compliance as of March 31, 2026. The company submitted a compliance plan within the required timeframe and believes it can demonstrate continued compliance in its next periodic report. Failure to do so will lead to a delisting from Nasdaq, impacting its ability to raise capital and trade publicly.
- : Ensysce Biosciences
- : Ensysce acquires Cy Biopharma for $77 million
Employee benefit plans
Ensysce Biosciences files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
About Ensysce Biosciences: questions and answers
What does Ensysce Biosciences do?
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the use of potent prescription drugs, reducing abuse and preventing overdoses.
Where is Ensysce Biosciences headquartered?
Ensysce Biosciences is headquartered in LA JOLLA, California, United States.
How many employees does Ensysce Biosciences have?
Ensysce Biosciences has about 12 employees.
What is the latest news on Ensysce Biosciences?
On Aug 25, 2026, SEC 8-K (8.01): On August 25, 2026, Ensysce Biosciences Inc. received notification from Nasdaq confirming that the company complies with the $2.5 million stockholders’ equity requirement under Rule 5550(b)(1). This followed a previous notice on May 21, 2026, regarding potential delisting due to non-
Is Ensysce Biosciences a public company?
Yes. Ensysce Biosciences is publicly traded under the ticker ENSC.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy